Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Labcorp (LH)

Labcorp raises 2026 guidance as Q3 adjusted EPS rises 14.5% to $4.78

Positive Impact 4 of 5 earnings

Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from a year earlier, and adjusted EPS of $4.78, up 14.5%. Diluted EPS rose 3.3% to $3.22, and the company raised its full-year 2026 revenue growth and adjusted EPS guidance. For shareholders, the headline measures improved and the higher outlook is the most significant change in the release.

Key points

  • Q3 2026 revenue was $3.81 billion versus $3.56 billion, up 6.9%; organic growth was 5.5%.
  • Diluted EPS was $3.22 versus $3.12, up 3.3%; adjusted EPS was $4.78 versus $4.18, up 14.5%.
  • Full-year 2026 adjusted EPS guidance was raised to $18.30 to $18.70 from $18.10 to $18.55; enterprise revenue growth guidance was raised to 5.9% to 6.7%.
  • Three acquisition agreements were signed after the quarter ended, including Millennium Health and the Myriad Genetics Prenatal Health business, subject to regulatory approvals.

The filing

CompanyLabcorp (LH)
Form8-K, current report
Filed with the SECOct 28, 2026, 6:57 AM ET
Accession number0000920148-26-000213

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.